Atlas Trials

Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma

11 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma

RecordFirmDate
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma (NCT05202782)Northwestern University2022-03-21
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800)M.D. Anderson Cancer Center2021-10-13
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma (NCT04432506)M.D. Anderson Cancer Center2020-07-27
Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy (NCT04870853)M.D. Anderson Cancer Center2020-04-02
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT03103971)Fred Hutchinson Cancer Center2017-11-03
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02706405)Fred Hutchinson Cancer Center2016-11-15
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (NCT02628405)Academic and Community Cancer Research United2016-05-20

Track Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.